Protagonist Therapeutics Inc [PTGX] stock prices are down -0.59% to $94.79 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PTGX shares have gain 5.03% over the last week, with a monthly amount glided 13.88%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Protagonist Therapeutics Inc [NASDAQ: PTGX] stock has seen the most recent analyst activity on September 17, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $72. Previously, Leerink Partners started tracking the stock with Outperform rating on September 12, 2025, and set its price target to $73. On June 17, 2025, Citigroup initiated with a Buy rating and assigned a price target of $72 on the stock. Goldman started tracking the stock assigning a Neutral rating and suggested a price target of $47 on December 06, 2024. BMO Capital Markets initiated its recommendation with an Outperform and recommended $62 as its price target on December 06, 2024. Wedbush started tracking with an Outperform rating for this stock on November 05, 2024, and assigned it a price target of $58. In a note dated September 24, 2024, TD Cowen initiated a Buy rating and provided a target price of $65 on this stock.
The stock price of Protagonist Therapeutics Inc [PTGX] has been fluctuating between $33.70 and $95.39 over the past year. Currently, Wall Street analysts expect the stock to reach $90.67 within the next 12 months. Protagonist Therapeutics Inc [NASDAQ: PTGX] shares were valued at $94.79 at the most recent close of the market. An investor can expect a potential drop of -4.35% based on the average PTGX price forecast.
Analyzing the PTGX fundamentals
The Protagonist Therapeutics Inc [NASDAQ:PTGX] reported sales of 209.22M for trailing twelve months, representing a surge of 0.79%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at 0.24%, and Net Profit Margin reading is 0.22%. To continue investigating profitability, this company’s Return on Assets is posted at 0.07, Equity is 0.07 and Total Capital is 0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 93.79 points at the first support level, and at 92.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 96.16, and for the 2nd resistance point, it is at 97.54.
Ratios To Look Out For
It’s worth pointing out that Protagonist Therapeutics Inc [NASDAQ:PTGX]’s Current Ratio is 13.05. As well, the Quick Ratio is 13.05, while the Cash Ratio is 2.53. Considering the valuation of this stock, the price to sales ratio is 28.32, the price to book ratio is 9.17 and price to earnings (TTM) ratio is 149.65.
Transactions by insiders
Recent insider trading involved MOLINA ARTURO MD, Chief Medical Officer, that happened on Nov 17 ’25 when 2712.0 shares were sold. Director, Waddill William D. completed a deal on Oct 10 ’25 to sell 12000.0 shares. Meanwhile, Director WILLIAM WADDILL bought 12000.0 shares on Oct 10 ’25.
